Gliris-MV 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1 mg, Metformin 500 mg, and Voglibose 0.2 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, reducing postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting steady plasma concentrations and improved patient compliance. Gliris-MV 1 Tablet SR is indicated for patients inadequately controlled on diet, exercise, and monotherapy, offering a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of type 2 diabetes. It is essential to monitor renal function and liver enzymes periodically during therapy. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, as well as hypoglycemia due to sulfonylurea action. This medication should be used under medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes.